Literature DB >> 9434920

Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gram-negative sepsis.

M Mohr1, L Englisch, A Roth, H Burchardi, S Zielmann.   

Abstract

OBJECTIVE: The evaluation of incidences and relating factors of severe persisting critical illness polyneuropathy (CIP) in survivors of multiple organ failure (MOF).
DESIGN: Prospective study with an entry period of 24 months. Electrophysiological studies for the diagnosis of CIP were performed 1 or 2 days before the patients were discharged from the intensive care unit (ICU). Factors which might have been related to the development of CIP were identified by a retrospective chart analysis.
SETTING: The interdisciplinary ICU of a university hospital. PATIENTS: Thirty-three patients who survived MOF. Sixteen of these critically ill patients developed severe sepsis due to nosocomial infections with gram-negative bacteria.
RESULTS: In seven survivors of MOF and sepsis typical electrophysiological features of CIP, like spontaneous fibrillations and low compound muscle action potentials, were detectable at the time of discharge from the ICU. Seventeen patients with MOF following multiple trauma who developed no sepsis, and nine survivors of MOF with sepsis showed no signs of persisting CIP at the end of their ICU stay. Chart analysis revealed that eight survivors of MOF with sepsis and without the development of CIP had been treated with intravenous immunoglobulin (IVIG) with a dosage of 0.3 g/kg per day for 3 days immediately (within 24 h) after the diagnosis of sepsis. Four out of seven patients with MOF and sepsis who developed CIP were transferred to our ICU after the onset of sepsis and had not received IVIG treatment. The IVIG treatment in three patients was delayed for more than 24 h after the diagnosis of sepsis and was then omitted. Obviously not related to the development of CIP were aminoglycoside antibiotics, steroids, nutritional disturbances and episodes of hypotension or hypoxia. Neuromuscular blocking agents were not used during intensive care treatment.
CONCLUSIONS: A high incidence of severe CIP persisting until the day of discharge from the ICU was related to gram-negative sepsis but not to MOF alone. Retrospective chart analysis suggested that early application of IVIG may prevent or mitigate this severe complication. However, these results have to be confirmed in a prospective, placebo-controlled study.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9434920     DOI: 10.1007/s001340050471

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  30 in total

1.  Comparison of early IgM-enriched immunoglobulin vs polyvalent IgG administration in score-identified postcardiac surgical patients at high risk for sepsis.

Authors:  G Pilz; R Appel; E Kreuzer; K Werdan
Journal:  Chest       Date:  1997-02       Impact factor: 9.410

Review 2.  Mechanisms of action of intravenous immune globulin in immune-mediated diseases.

Authors:  L Mouthon; S V Kaveri; S H Spalter; S Lacroix-Desmazes; C Lefranc; R Desai; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1996-05       Impact factor: 4.330

Review 3.  Supplemental immune globulins in sepsis: a critical appraisal.

Authors:  K Werdan; G Pilz
Journal:  Clin Exp Immunol       Date:  1996-05       Impact factor: 4.330

4.  Prolonged paralysis after treatment with neuromuscular junction blocking agents.

Authors:  J L Gooch; M R Suchyta; J M Balbierz; J H Petajan; T P Clemmer
Journal:  Crit Care Med       Date:  1991-09       Impact factor: 7.598

5.  Failure of high dose intravenous immunoglobulins to alter the clinical course of critical illness polyneuropathy.

Authors:  E F Wijdicks; J R Fulgham
Journal:  Muscle Nerve       Date:  1994-12       Impact factor: 3.217

6.  Capillary permeability in septic patients.

Authors:  H Ellman
Journal:  Crit Care Med       Date:  1984-08       Impact factor: 7.598

7.  Prolonged myasthenic syndrome after one week of muscle relaxants.

Authors:  G Benzing; S T Iannaccone; K E Bove; P J Keebler; L L Shockley
Journal:  Pediatr Neurol       Date:  1990 May-Jun       Impact factor: 3.372

8.  Critical illness polyneuropathy. A complication of sepsis and multiple organ failure.

Authors:  D W Zochodne; C F Bolton; G A Wells; J J Gilbert; A F Hahn; J D Brown; W A Sibbald
Journal:  Brain       Date:  1987-08       Impact factor: 13.501

9.  The role of polyneuropathy in motor convalescence after prolonged mechanical ventilation.

Authors:  F S Leijten; J E Harinck-de Weerd; D C Poortvliet; A W de Weerd
Journal:  JAMA       Date:  1995-10-18       Impact factor: 56.272

10.  Acute polyneuropathy in critically ill patients.

Authors:  J B Lopez Messa; A García
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

View more
  22 in total

1.  Critical Illness Polyneuropathy.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-11       Impact factor: 3.598

2.  Critical illness polyneuropathy after septic peritonitis in a boy with nephrotic syndrome.

Authors:  Eriko Kikuchi; Masaya Kubota; Koichi Kamei; Shuichi Ito
Journal:  Pediatr Nephrol       Date:  2010-03-16       Impact factor: 3.714

3.  Review of Critical Illness Myopathy and Neuropathy.

Authors:  Starane Shepherd; Ayush Batra; David P Lerner
Journal:  Neurohospitalist       Date:  2016-08-23

Review 4.  Intensive care unit-related generalized neuromuscular weakness due to critical illness polyneuropathy/myopathy in critically ill patients.

Authors:  Efstratios Apostolakis; Nikolaos A Papakonstantinou; Nikolaos G Baikoussis; George Papadopoulos
Journal:  J Anesth       Date:  2014-07-01       Impact factor: 2.078

5.  [Critical illness myopathy and neuropathy (CRIMYN). Electroneurographic classification].

Authors:  P Baum; S Bercker; T Villmann; J Classen; W Hermann
Journal:  Nervenarzt       Date:  2011-04       Impact factor: 1.214

Review 6.  [Therapy of organ failure in primary extracardiac diseases].

Authors:  S Reith; K Werdan
Journal:  Internist (Berl)       Date:  2005-03       Impact factor: 0.743

7.  Role of endotoxin in the pathogenesis of critical illness polyneuropathy.

Authors:  B Mohammadi; I Schedel; K Graf; A Teiwes; H Hecker; B Haameijer; D Scheinichen; S Piepenbrock; R Dengler; J Bufler
Journal:  J Neurol       Date:  2008-02-20       Impact factor: 4.849

Review 8.  Interventions for preventing critical illness polyneuropathy and critical illness myopathy.

Authors:  Greet Hermans; Bernard De Jonghe; Frans Bruyninckx; Greet Van den Berghe
Journal:  Cochrane Database Syst Rev       Date:  2014-01-30

Review 9.  The incidence of intensive care unit-acquired weakness syndromes: A systematic review.

Authors:  Richard Td Appleton; John Kinsella; Tara Quasim
Journal:  J Intensive Care Soc       Date:  2014-12-18

Review 10.  Neuromuscular dysfunction acquired in critical illness: a systematic review.

Authors:  Robert D Stevens; David W Dowdy; Robert K Michaels; Pedro A Mendez-Tellez; Peter J Pronovost; Dale M Needham
Journal:  Intensive Care Med       Date:  2007-07-17       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.